Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average – Should You Sell?

Precipio, Inc. (NASDAQ:PRPO)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $20.29 and traded as low as $19.52. Precipio shares last traded at $19.80, with a volume of 32,703 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Precipio Stock Down 1.3%

The company’s 50-day simple moving average is $23.79 and its two-hundred day simple moving average is $20.29. The firm has a market capitalization of $34.65 million, a P/E ratio of -24.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $6.77 million for the quarter. Precipio had a negative net margin of 5.50% and a negative return on equity of 10.07%.

Institutional Trading of Precipio

A number of hedge funds and other institutional investors have recently bought and sold shares of PRPO. AMH Equity Ltd lifted its position in shares of Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares in the last quarter. Evernest Financial Advisors LLC purchased a new stake in Precipio in the 3rd quarter worth approximately $374,000. Topline Capital Management LLC bought a new stake in Precipio during the 3rd quarter worth approximately $1,158,000. Susquehanna International Group LLP purchased a new position in Precipio during the third quarter valued at approximately $194,000. Finally, Geode Capital Management LLC boosted its position in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares during the period. Hedge funds and other institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.